WBR0121: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (refreshing WBR questions)
 
(10 intermediate revisions by 2 users not shown)
Line 1: Line 1:
{{WBRQuestion
{{WBRQuestion
|QuestionAuthor=William J Gibson (reviewed by {{Rim}})
|QuestionAuthor=William J Gibson (Reviewed by {{YD}})
|ExamType=USMLE Step 1
|ExamType=USMLE Step 1
|MainCategory=Genetics
|MainCategory=Genetics
Line 10: Line 10:
|MainCategory=Genetics
|MainCategory=Genetics
|MainCategory=Genetics
|MainCategory=Genetics
|MainCategory=Genetics
|SubCategory=Reproductive, General Principles
|MainCategory=Genetics
|SubCategory=Reproductive, General Principles
|MainCategory=Genetics
|MainCategory=Genetics
|SubCategory=Reproductive, General Principles
|SubCategory=Reproductive, General Principles
Line 21: Line 25:
|MainCategory=Genetics
|MainCategory=Genetics
|SubCategory=Reproductive, General Principles
|SubCategory=Reproductive, General Principles
|Prompt=A 56-year-old woman presents to her primary care physician complaining of abdominal pain, bloating, and early satiety. She explains that these symptoms have been increasing in severity over the past several weeks. The physician notes mild tenderness with palpation on abdominal exam. The patient is then referred to an OB/GYN specialist where a pelvic exam is performed. Pelvic exam reveals a large left adnexal mass. Laboratory studies are significant for elevated CA-125. Abdominopelvic CT scan reveals a large left ovarian solid mass that has extended to, but not invaded, the omentum. The patient udergoes total abdominal hysterectomy and bilateral bilateral salpingo-oophorectomy (TAH-BSO).  After resection, the pathologist makes the diagnosis of high-grade serous ovarian adenocarcinoma. Molecular analysis demonstrates the following sequencing results of the ''TP53'' gene:
|Prompt=A 56-year-old woman presents to her primary care physician complaining of abdominal pain, bloating, and early satiety. She explains that these symptoms have been increasing in severity over the past several weeks. The physician notes mild tenderness with palpation on abdominal exam. The patient is then referred to an OB/GYN specialist where a pelvic exam is performed. Pelvic exam reveals a large left adnexal mass. Laboratory studies are significant for elevated CA-125 blood levels. Abdominopelvic CT scan reveals a large left ovarian solid mass that extends to the omentum. The patient undergoes total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH-BSO).  After resection, the pathologist makes the diagnosis of high-grade serous ovarian adenocarcinoma. Sanger DNA sequencing of the TP53 gene reveals a single mutation pictured in the chromatogram below.
[[File:Hetmutation.png|center]]
[[File:Hetmutation.png]]


Which of the following is the most appropriate term for the molecular effect of this mutation?
Which of the following is the most appropriate term for the molecular effect of this mutation?
|Explanation=p53 is a transcriprtional activator that controls cell fate and initiates cell cycle arrest, senescence, and apoptosis. Mutations of p53 usually affect the core domain and exhibit dominant negative effect of the mutant allele on the wild-type allele. In this vignette, the [[mutation]] demonstrates a heterozygous mutation, meaning that one copy of the ''[[TP53]]'' gene is mutated and the other is not. A heterozygous mutation which leads to a phenotype (in this cas cancer) is an example of a dominant negative mutation.  On the molecular level, the [[p53]] protein normally forms a homotetramer, a hollow skewed cube that binds to specific DNA regions at the level of p53 core domains.
|Explanation=The TP53 gene encodes the p53 protein, the most commonly disrupted tumor suppressor in human cancer.  p53 is a [[transcriprtional activator]] that controls cell fate and initiates [[cell cycle]] arrest, [[senescence]], and [[apoptosis]]. Mutations of p53 usually affect the core domain that binds to DNA and exhibit dominant negative effect of the mutant allele on the wild-type allele. In this vignette, the Sanger sequencing chromatogram demonstrates a [[heterozygous mutation]], meaning that one copy of the ''[[TP53]]'' gene is mutated and the other is not. A heterozygous mutation which leads to a [[phenotype]] (in this case cancer) is an example of a [[dominant negative mutation]].


Unlike mutations of other tumor suppressors, a mutation of a single p53 allele leads to a significant loss-of-function effect due to the dominant negative effect of the mutant allele that disrupts the effect of the normal wild-type allele.  One hypothesis suggests that when one mutant ''TP53'' allele joins the wild-type homotetramer, the homotetramer is heterotetramerized; and wild-type p53 function loses its conformation and is inactivated. Thus, one mutated allele causes the p53 protein to lose approximately 15/16 of its biological function. On the other hand, a deletion of p53 would cause a 50% decrease in its biological function. For this reason, p53 is more likely to be mutated than deleted. Dominant mutant p53 proteins are notoriously over-expressed in ovarian cancers, where cross-talk between the wild-type p53 and the dominant mutant p53 protein has compromised all attempts of gene therapy and efforts that target p53 in these cancers.
Unlike mutations of other tumor suppressors, a mutation of a single ''TP53'' allele leads to a significant loss-of-function effect due to the dominant negative effect of the mutant allele that disrupts the effect of the normal wild-type allele. On the molecular level, the [[p53]] protein normally forms a [[homotetramer]], a hollow skewed cube that binds to specific DNA regions at the level of p53 core domains.  One hypothesis suggests that when one mutant ''TP53'' allele joins the wild-type homotetramer, the homotetramer is heterotetramerized; and the wild-type p53 loses its conformation and is inactivated. Thus, one mutated allele causes the p53 protein to lose approximately 15/16 of its biological function. On the other hand, a deletion of p53 would cause only a 50% decrease in its biological function. For this reason, p53 is more likely to be mutated than deleted in cancers. Mutations of the TP53 gene are detected in approximately 95% of ovarian cancers and dominant negative mutations compose a majority of these mutations.
|AnswerA=Loss of heterozygosity
|AnswerA=Loss of heterozygosity
|AnswerAExp=While loss of heterozygosity is a term commonly used with tumor suppressors, the mutation in this case is heterozygous.
|AnswerAExp=While loss of heterozygosity is a term commonly used with tumor suppressors, the mutation in this case is heterozygous.
|AnswerB=Dominant negative mutation
|AnswerB=Dominant negative mutation
|AnswerBExp=A dominant negative mutation refers to a mutation whose gene product  negates the function of its normal, wild-type counterpart.
|AnswerBExp=A [[dominant negative mutation]] refers to a mutation whose gene product  negates the function of its normal, wild-type counterpart.
|AnswerC=Epistasis
|AnswerC=Epistasis
|AnswerCExp=[[Epistasis]] is a phenomenon in which the expression of one gene depends on the presence of other "modifier genes(s)". Both genes interact to control a single phenotype.
|AnswerCExp=[[Epistasis]] is a phenomenon in which the expression of one gene depends on the presence of other "modifier genes(s)". Both genes interact to control a single phenotype.
|AnswerD=Haploinsufficiency
|AnswerD=Haploinsufficiency
|AnswerDExp=While mutation of one allele causes disease, the molecular mechanism of the mutation observed in this vignette is not simply attributed to decreased function of the monomeric gene product. In this case, the mutant protein interferes with the function of another wild-type gene
|AnswerDExp=While mutation of one allele causes disease, the molecular mechanism of the mutation observed in this vignette is not simply attributed [[haploinsufficiency]], a decreased function of the monomeric gene product. In this case, the mutant protein interferes with the function of another wild-type gene
|AnswerE=Loss-of-function
|AnswerE=Loss-of-function
|AnswerEExp=While the observed mutation may cause the protein to lose some of its biological function, it does so in a dominant negative manner.  Loss-of-function mutations typically act in a recessive manner at the molecular level.
|AnswerEExp=While the observed mutation may cause the protein to lose some of its biological function, it does so in a dominant negative manner.  Loss-of-function mutations typically act in a recessive manner at the molecular level.
|EducationalObjectives=A dominant negative mutation refers to a mutation whose gene product  negates the function of its normal, wild-type counterpart. Dominant mutant p53 proteins are notoriously over-expressed in ovarian cancers
|EducationalObjectives=A dominant negative mutation refers to a mutation whose gene product  negates the function of its normal, wild-type counterpart. Mutant TP53 mutations are found in 95% of ovarian cancers.
|References=Aramayo R, Sherman MB, Brownless K, et al. Quaternary structure of the specific p53-DNA complex reveals the mechanism of p53 mutant dominance. Nucleic Acids Res. 2011;39(20):8960-71
|References=Aramayo R, Sherman MB, Brownless K, et al. Quaternary structure of the specific p53-DNA complex reveals the mechanism of p53 mutant dominance. Nucleic Acids Res. 2011;39(20):8960-71


Line 45: Line 49:
First Aid 2014 page 76
First Aid 2014 page 76
|RightAnswer=B
|RightAnswer=B
|WBRKeyword=TP53, p53, Mutation, Genetics, Dominant, Negative, Dominant negative, Homotetramer, Heterotetramer, Ovarian, Cancer, Adenocarcinoma, Adnexal, Mass, Adnexal, mass, OB/GYN, Haploinsufficiency, Epistatis, Epigenetics, Loss of function, Loss of heterozygosity, Mutation, Tumor suppressor gene, Tumor suppressor, Apoptosis, Cell cycle arrest, Cell cycle, p53, TP53
|WBRKeyword=Mutation, Genetics, Dominant, Negative, Dominant negative, Homotetramer, Heterotetramer, Ovarian, Cancer, Adenocarcinoma, Adnexal, Mass, Adnexal, mass, OB/GYN, Haploinsufficiency, Epistatis, Epigenetics, Loss of function, Loss of heterozygosity, Mutation, Tumor suppressor gene, Tumor suppressor, Apoptosis, Cell cycle arrest, Cell cycle, p53, TP53
|Approved=Yes
|Approved=Yes
}}
}}

Latest revision as of 23:24, 27 October 2020

 
Author [[PageAuthor::William J Gibson (Reviewed by Yazan Daaboul, M.D.)]]
Exam Type ExamType::USMLE Step 1
Main Category MainCategory::Genetics
Sub Category SubCategory::Reproductive, SubCategory::General Principles
Prompt [[Prompt::A 56-year-old woman presents to her primary care physician complaining of abdominal pain, bloating, and early satiety. She explains that these symptoms have been increasing in severity over the past several weeks. The physician notes mild tenderness with palpation on abdominal exam. The patient is then referred to an OB/GYN specialist where a pelvic exam is performed. Pelvic exam reveals a large left adnexal mass. Laboratory studies are significant for elevated CA-125 blood levels. Abdominopelvic CT scan reveals a large left ovarian solid mass that extends to the omentum. The patient undergoes total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH-BSO). After resection, the pathologist makes the diagnosis of high-grade serous ovarian adenocarcinoma. Sanger DNA sequencing of the TP53 gene reveals a single mutation pictured in the chromatogram below.

Which of the following is the most appropriate term for the molecular effect of this mutation?]]

Answer A AnswerA::Loss of heterozygosity
Answer A Explanation AnswerAExp::While loss of heterozygosity is a term commonly used with tumor suppressors, the mutation in this case is heterozygous.
Answer B AnswerB::Dominant negative mutation
Answer B Explanation [[AnswerBExp::A dominant negative mutation refers to a mutation whose gene product negates the function of its normal, wild-type counterpart.]]
Answer C AnswerC::Epistasis
Answer C Explanation [[AnswerCExp::Epistasis is a phenomenon in which the expression of one gene depends on the presence of other "modifier genes(s)". Both genes interact to control a single phenotype.]]
Answer D AnswerD::Haploinsufficiency
Answer D Explanation [[AnswerDExp::While mutation of one allele causes disease, the molecular mechanism of the mutation observed in this vignette is not simply attributed haploinsufficiency, a decreased function of the monomeric gene product. In this case, the mutant protein interferes with the function of another wild-type gene]]
Answer E AnswerE::Loss-of-function
Answer E Explanation AnswerEExp::While the observed mutation may cause the protein to lose some of its biological function, it does so in a dominant negative manner. Loss-of-function mutations typically act in a recessive manner at the molecular level.
Right Answer RightAnswer::B
Explanation [[Explanation::The TP53 gene encodes the p53 protein, the most commonly disrupted tumor suppressor in human cancer. p53 is a transcriprtional activator that controls cell fate and initiates cell cycle arrest, senescence, and apoptosis. Mutations of p53 usually affect the core domain that binds to DNA and exhibit dominant negative effect of the mutant allele on the wild-type allele. In this vignette, the Sanger sequencing chromatogram demonstrates a heterozygous mutation, meaning that one copy of the TP53 gene is mutated and the other is not. A heterozygous mutation which leads to a phenotype (in this case cancer) is an example of a dominant negative mutation.

Unlike mutations of other tumor suppressors, a mutation of a single TP53 allele leads to a significant loss-of-function effect due to the dominant negative effect of the mutant allele that disrupts the effect of the normal wild-type allele. On the molecular level, the p53 protein normally forms a homotetramer, a hollow skewed cube that binds to specific DNA regions at the level of p53 core domains. One hypothesis suggests that when one mutant TP53 allele joins the wild-type homotetramer, the homotetramer is heterotetramerized; and the wild-type p53 loses its conformation and is inactivated. Thus, one mutated allele causes the p53 protein to lose approximately 15/16 of its biological function. On the other hand, a deletion of p53 would cause only a 50% decrease in its biological function. For this reason, p53 is more likely to be mutated than deleted in cancers. Mutations of the TP53 gene are detected in approximately 95% of ovarian cancers and dominant negative mutations compose a majority of these mutations.
Educational Objective: A dominant negative mutation refers to a mutation whose gene product negates the function of its normal, wild-type counterpart. Mutant TP53 mutations are found in 95% of ovarian cancers.
References: Aramayo R, Sherman MB, Brownless K, et al. Quaternary structure of the specific p53-DNA complex reveals the mechanism of p53 mutant dominance. Nucleic Acids Res. 2011;39(20):8960-71

Willis A, Jung EJ, Wakefield T, et al. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes Oncogene. 2004;23:2330-2338

First Aid 2014 page 76]]

Approved Approved::Yes
Keyword WBRKeyword::Mutation, WBRKeyword::Genetics, WBRKeyword::Dominant, WBRKeyword::Negative, WBRKeyword::Dominant negative, WBRKeyword::Homotetramer, WBRKeyword::Heterotetramer, WBRKeyword::Ovarian, WBRKeyword::Cancer, WBRKeyword::Adenocarcinoma, WBRKeyword::Adnexal, WBRKeyword::Mass, WBRKeyword::Adnexal, WBRKeyword::mass, WBRKeyword::OB/GYN, WBRKeyword::Haploinsufficiency, WBRKeyword::Epistatis, WBRKeyword::Epigenetics, WBRKeyword::Loss of function, WBRKeyword::Loss of heterozygosity, WBRKeyword::Mutation, WBRKeyword::Tumor suppressor gene, WBRKeyword::Tumor suppressor, WBRKeyword::Apoptosis, WBRKeyword::Cell cycle arrest, WBRKeyword::Cell cycle, WBRKeyword::p53, WBRKeyword::TP53
Linked Question Linked::
Order in Linked Questions LinkedOrder::